MSD S-PLEX · fg/mL Sensitivity

10–100× Beyond Standard ECL

MSD S-PLEX Ultrasensitive Cytokine & Biomarker Assay Services

Detect cytokines and immune mediators at femtogram-per-milliliter concentrations — 10 to 100 times below the lower limit of standard immunoassays — using MSD's enhanced electrochemiluminescence signal amplification technology, for precious samples where every microliter and every molecule counts.

Many biologically significant cytokines — IL-4, IL-5, IL-13, and others — circulate at concentrations below 0.1 pg/mL in plasma, beneath the reliable quantification limit of conventional ELISA and standard multiplex platforms. When baseline cytokine levels in healthy research participants fall below the assay's LLOQ, subtle disease-associated changes, treatment effects, and longitudinal trajectories are invisible to the assay. S-PLEX addresses this through an additional antibody-based signal amplification layer that multiplies the number of SULFO-TAG labels per captured analyte, pushing the detection floor into the femtogram domain while preserving the background-free ECL advantage.

Inquire About S-PLEX How S-PLEX Works

Applications Requiring Ultrasensitive Cytokine Detection

Immunoassay sensitivity is conventionally reported as the lower limit of detection (LOD) — the lowest concentration statistically distinguishable from zero. But the practical metric that matters for research is the lower limit of quantification (LLOQ) — the lowest concentration that can be measured with acceptable precision (CV <20%). The gap between LOD and LLOQ is where biologically meaningful cytokine signals reside, and where standard assays fall short.

 Scenarios Where S-PLEX Matters
Baseline cytokine levels in healthy populations: IL-4, IL-5, IL-13, and other Th2 cytokines typically circulate at <1 pg/mL in plasma — below the LLOQ of standard multiplex assays. S-PLEX brings these into the quantifiable range, enabling group comparisons that standard assays cannot support.
Early treatment effects: When an investigational therapy suppresses an already low-abundance cytokine, standard assays may report "below LLOQ" for both pre- and post-treatment samples — masking a real biological effect. S-PLEX provides the resolution to detect these changes.
Precious sample volumes: Pediatric samples, CSF, longitudinal aliquots nearing depletion — when sample volume is limiting, the assay must extract maximum information from every microliter. S-PLEX requires only 25 µL per well while delivering the highest sensitivity available on the MSD platform.
Biomarker discovery in early disease: The earliest cytokine perturbations in disease may occur at concentrations far below those seen in established pathology. S-PLEX extends the measurable range downward, potentially revealing signals missed by standard-sensitivity approaches.

Standard MSD vs. S-PLEX — Representative LOD Values

Approximate lower limit of detection (LOD) for key low-abundance cytokines in plasma. Actual values vary by antibody lot and matrix — contact us for current lot-specific performance data.

Analyte	Standard MSD LOD	S-PLEX LOD	Improvement
IL-4	~0.5 pg/mL	~0.01–0.02 pg/mL	25–50×
IL-5	~0.3 pg/mL	~0.01–0.02 pg/mL	15–30×
IL-13	~0.5 pg/mL	~0.02–0.05 pg/mL	10–25×
IL-17A	~0.3 pg/mL	~0.01–0.03 pg/mL	10–30×
TNF-α	~0.1 pg/mL	~0.005–0.01 pg/mL	10–20×

Values are illustrative, based on manufacturer product literature and published characterization data for representative S-PLEX assays. Lot-specific LOD and LLOQ values are provided with each project datasheet. For Research Use Only.

S-PLEX Signal Amplification Technology

The signal amplification architecture that extends ECL detection 10–100× beyond standard MSD assays.

Sensitivity Limitations of Standard Immunoassays

In a standard sandwich immunoassay, each captured analyte molecule is labeled with one detection antibody carrying one signal-generating moiety (SULFO-TAG, enzyme, or fluorophore). At sub-pg/mL concentrations, the absolute number of captured molecules per well is so low that the cumulative signal approaches the instrument's noise floor. The solution is not brighter labels — it's more labels per captured molecule.

1. Primary Antibody Capture

Target cytokine captured by the spot-coated capture antibody on the carbon electrode surface — identical to standard MSD.

2. S-PLEX Amplifier Antibody

An additional amplifier antibody — specific to the detection antibody species/Fc region — binds multiple detection antibodies per captured analyte, creating a branched labeling structure that multiplies SULFO-TAG density per target molecule.

3. Multiplied SULFO-TAG Signal

Each amplifier carries multiple SULFO-TAG labels; combined with multiple amplifiers per analyte, the signal per captured molecule increases 10–100× — pushing the LOD into the fg/mL range without increasing non-specific binding proportionally.

4. Background-Free ECL Readout

Critical advantage: the amplified signal is still generated by electrical excitation at the electrode surface. Unbound SULFO-TAG-labeled amplifiers in the bulk solution do not contribute to background — only labels within the ~10 nm electrical excitation layer emit light.

S-PLEX Assay Specifications

TechnologyMSD S-PLEX (Amplified ECL)

LOD<0.01–0.05 pg/mL (fg/mL range)

LLOQ~0.05–0.1 pg/mL (target-dependent)

Sensitivity Gain10–100× vs. standard MSD

Dynamic Range5+ logs (0.05–10,000 pg/mL)

FormatSingle-plex per well

Sample Volume25 µL per well

Intra-Assay CV<10%

Inter-Assay CV<15%

Plate Format96-well MULTI-ARRAY

Read Time~70 seconds per plate

Available TargetsSelect cytokines; contact for current catalog

S-PLEX vs. Standard MSD: When Sensitivity Matters

fg/mL Detection S-PLEX

Multiplex Capability V-PLEX

Sample Efficiency S-PLEX

Data Richness V-PLEX

Low-Abundance Targets S-PLEX

S-PLEX sacrifices multiplex capability for maximum single-analyte sensitivity. For studies requiring both multiplex and ultrasensitive detection, a hybrid approach (V-PLEX for broad profiling + S-PLEX for select low-abundance targets) often provides the optimal balance.

Research Applications for S-PLEX Cytokine Detection

Th2 Cytokines in Allergy & Asthma

IL-4, IL-5, and IL-13 are central to Type 2 inflammation but circulate at <1 pg/mL — below standard assay LLOQ. S-PLEX enables quantification of these key Th2 drivers at baseline, supporting mechanistic research and therapeutic monitoring in allergic and respiratory disease programs.

Neuroinflammation & Neurodegeneration

CSF cytokine concentrations are inherently low, and sample volume is precious. S-PLEX's fg/mL sensitivity from 25 µL addresses both constraints — enabling quantification of neuroinflammatory mediators that standard assays report as below detection limit.

Vaccine & Adjuvant Research

Early innate cytokine responses to vaccination occur at low concentrations within narrow time windows. S-PLEX captures these subtle, transient signals — supporting adjuvant comparison studies and correlates of protection research where standard assays lack resolution.

Pediatric & Volume-Limited Studies

When total blood volume restricts sample availability — pediatric cohorts, microsampling studies, or multi-analyte panels from a single small aliquot — S-PLEX maximizes the data extracted from every 25 µL while maintaining fg/mL sensitivity.

Therapeutic PD Biomarkers

When an investigational drug suppresses a target cytokine below the standard assay's quantifiable range, the pharmacodynamic effect is unmeasurable. S-PLEX extends the measurable range downward, enabling PD assessment even at near-complete target suppression.

Early Disease Biomarker Discovery

The earliest cytokine perturbations preceding clinical disease may occur at fg/mL concentrations. S-PLEX provides the analytical sensitivity to explore this sub-threshold biomarker space in longitudinal pre-disease cohorts and at-risk population studies.

S-PLEX Assay Service Details

Service Package

Item	Full Service	Kit Only
Sample Processing	Included	— Self-run
S-PLEX Amplification	Included in protocol	Reagents provided
Standard Curve	8-point, each plate	Calibrator provided
QC Samples	3 levels, duplicate	— User-prepared
Data Analysis	Full report with QC metrics	— Self-analysis

For Research Use Only. Not for diagnostic procedures.

How to Get Started

Assess Need

Share your analytes and expected concentration range. We'll evaluate whether S-PLEX is warranted or standard MSD sensitivity is sufficient for your targets.

Ship

Send your samples on dry ice following matrix-specific guidelines. 25 µL per well — precious sample volumes preserved.

Receive fg/mL Data

Receive your S-PLEX data package with concentrations quantified in the fg/mL range and full QC documentation.

Unsure about the expected concentration range for your analyte? Ask about a pilot S-PLEX run on a small subset of samples — confirm quantifiability before committing to a full study.

S-PLEX vs. Other Ultrasensitive Immunoassay Platforms

Sensitivity comparison for low-abundance cytokine detection in research applications.

Feature	MSD S-PLEX	Simoa (Quanterix)	Standard MSD	Conventional ELISA
LOD	fg/mL	fg/mL	0.05–1 pg/mL	1–50 pg/mL
Signal Amplification	Antibody-based branched labeling	Single-molecule counting in femtoliter wells	Standard SULFO-TAG labeling	Enzymatic amplification
Dynamic Range	5+ logs	4–5 logs	4–5 logs	2–3 logs
Background	Near-zero (ECL proximity)	Low (confined wells)	Near-zero (ECL proximity)	Enzymatic noise
Sample Volume	25 µL	~100 µL	25 µL	100 µL
Throughput	96-well / 70 sec	~60 samples/hr	96-well / 70 sec	96-well batch
Format	Single-plex per well	Single-plex per test	1–54-plex	Single-plex

What You Receive

Quantitative report with fg/mL-level concentrations — analyte concentrations quantified in the femtogram range with standard curve parameters, QC metrics, and LOD/LLOQ confirmation (Excel + PDF)
Raw ECL data — per-well signal values, plate layout maps, and calibration curve plots — directly usable for independent statistical analysis
S-PLEX amplification documentation — lot-specific amplifier reagent information and signal-to-background data confirming the sensitivity gain for your target analyte
Methods summary — detailed protocol including the S-PLEX amplification steps, suitable for publication Methods sections
Sensitivity consultation — post-delivery discussion of whether the S-PLEX sensitivity was sufficient for your research question, and recommendations for follow-up studies if needed

Why Choose S-PLEX

10–100× beyond standard immunoassay sensitivity: S-PLEX delivers fg/mL LOD — capturing cytokine signals that standard multiplex panels and ELISA report as "below detection limit." This is not an incremental improvement; it is a qualitative difference in what you can measure.
ECL proximity-gated background control: the amplifier multiplies signal from surface-captured analyte without proportionally multiplying background from unbound reagents — SULFO-TAG labels beyond ~10 nm from the electrode do not emit. This is the key advantage over enzymatic amplification, where background increases with signal amplification.
Same platform, same sample volume: S-PLEX runs on the same MESO QuickPlex/SECTOR instruments and requires the same 25 µL as standard MSD — no new equipment, no additional sample. The only difference is the amplifier reagent added to the protocol.
LLOQ, not just LOD: S-PLEX pushes the lower limit of quantification — where you can measure with acceptable precision — into the fg/mL range, not just the limit of detection. This is the practical metric that determines whether you can detect group differences in low-abundance cytokines.
Hybrid workflow compatible: use V-PLEX or U-PLEX multiplex panels for broad profiling, then deploy S-PLEX single-plex for the 1–3 ultra-low-abundance targets where standard sensitivity is insufficient — all from the same sample set, on the same platform.

S-PLEX Frequently Asked Questions

How much more sensitive is S-PLEX compared to standard MSD assays?

S-PLEX typically achieves 10–100× lower LOD and LLOQ compared to standard MSD assays for the same analyte. For context: if a standard MSD assay has an LLOQ of 0.5 pg/mL for IL-4, the S-PLEX version may achieve an LLOQ of 0.01–0.05 pg/mL. The exact sensitivity gain varies by analyte, matrix, and antibody pair — contact us for analyte-specific S-PLEX performance data. The practical impact is that cytokines reported as "below LLOQ" in standard assays become quantifiable with S-PLEX, enabling group comparisons and treatment effect detection that were previously impossible.

Can S-PLEX be used in a multiplex format?

S-PLEX is a single-plex format — each well measures one analyte. The enhanced amplification step is optimized for single-analyte detection, and combining multiple S-PLEX assays in a single well would introduce cross-reactivity risks that could compromise the fg/mL sensitivity advantage. For studies requiring both multiplex coverage and ultrasensitive detection for specific low-abundance targets, a common strategy is: run a V-PLEX or U-PLEX multiplex panel for broad cytokine profiling, then run S-PLEX single-plex assays for the 1–3 targets where standard sensitivity is insufficient. Both approaches use the same 25 µL per well on the same instrument platform.

Is S-PLEX available for all cytokines?

S-PLEX is available for select targets where the antibody pair and amplification reagents have been qualified. The target catalog is actively expanding — current availability includes key low-abundance cytokines in the Th2 family (IL-4, IL-5, IL-13), inflammation markers, and select neurodegeneration targets. Contact our scientific team with your specific analytes of interest — we'll confirm current S-PLEX availability and discuss alternatives if your target is not yet supported. For targets not available as S-PLEX, standard MSD or U-PLEX may still provide sufficient sensitivity depending on your expected concentration range.

Does the S-PLEX amplification step increase non-specific background?

The S-PLEX amplifier design leverages ECL's inherent proximity-dependence to control background. SULFO-TAG labels emit light only when electrically stimulated within approximately 10 nm of the electrode surface. Amplifier-bound labels in the bulk solution — hundreds of nanometers away — do not contribute to the measured signal. This means the amplifier multiplies signal from surface-captured analyte without proportionally multiplying background from unbound reagents in solution. In practice, the signal-to-background ratio improves with amplification because the specific signal increases multiplicatively while non-specific binding increases additively.

How should I prepare samples for S-PLEX analysis?

Sample preparation for S-PLEX follows the same guidelines as standard MSD assays — the amplification step occurs entirely within the assay protocol, not during sample collection. For EDTA plasma: collect in EDTA tubes → centrifuge at 1,500×g for 10 min at 4°C → aliquot into polypropylene cryovials → freeze at −80°C. Ship on dry ice via overnight courier. Single-use aliquots recommended — avoid repeated freeze-thaw cycles. The enhanced sensitivity of S-PLEX makes pre-analytical consistency especially important: even minor variations in collection, processing, or storage can become detectable at fg/mL resolution. We provide detailed pre-analytical guidelines during study design.

Demo Assay Report

See How Your Assay Results Are Reported

Request a representative report to review how assay methods, standard curves, quality-control metrics, and quantitative results are presented.

Assay methods
Standard curves
QC metrics
Quantitative results

Representative formatContents vary by assay and project

RESULTS OVERVIEW

CREATIVE PROTEOMICSREPRESENTATIVE REPORT

PROTEIN & BIOMARKER ANALYSIS

Assay Report

Methods · Standard Curves · QC · Results

ASSAY SERVICESFOR RESEARCH USE ONLY

REPRESENTATIVE REPORT FORMAT Assay methods, QC metrics, and quantitative results

Demo report

Inquiry Basket

Inquiry